KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) EBITDA Margin (2016 - 2025)

Travere Therapeutics' EBITDA Margin history spans 13 years, with the latest figure at 2.0% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 8133.0% year-over-year to 2.0%; the TTM value through Dec 2025 reached 7.29%, up 13002.0%, while the annual FY2025 figure was 5.43%, 13188.0% up from the prior year.
  • EBITDA Margin reached 2.0% in Q4 2025 per TVTX's latest filing, down from 63.66% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 406.89% in Q3 2023 to a low of 329.91% in Q1 2024.
  • Average EBITDA Margin over 5 years is 118.28%, with a median of 112.28% recorded in 2021.
  • Peak YoY movement for EBITDA Margin: skyrocketed 65007bps in 2023, then plummeted -49305bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 64.59% in 2021, then crashed by -264bps to 235.29% in 2022, then increased by 17bps to 195.25% in 2023, then soared by 59bps to 79.33% in 2024, then skyrocketed by 103bps to 2.0% in 2025.
  • Per Business Quant, the three most recent readings for TVTX's EBITDA Margin are 2.0% (Q4 2025), 63.66% (Q3 2025), and 11.12% (Q2 2025).